Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Leqembi | lecanemab | Alzheimer’s disease | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Active | ||
Leqvio | inclisiran | Primary hypercholesterolemia | Reimburse with clinical criteria and/or conditions | Active | ||
Leqvio | inclisiran | Primary hypercholesterolemia | Do not reimburse | Complete | ||
Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
Levemir | Insulin detemir | Diabetes mellitus Type1, Pediatrics | Do not list | Complete | ||
Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Libtayo | cemiplimab | Basal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Libtayo | cemiplimab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Livmarli | maralixibat | Alagille syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Livtencity | maribavir | Post-transplant cytomegalovirus infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Lixiana NVAF | Edoxaban | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. | Reimburse with clinical criteria and/or conditions | Complete | ||
Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | ||
Lodalis | Colesevelam hydrochloride | Hypercholesterolemia | Do not list at the submitted price | Complete | ||
Lokelma | sodium zirconium cyclosilicate | Hyperkalemia, adults | Do not reimburse | Complete | ||
Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Complete | ||
Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lorbrena | Lorlatinib | Non-Small Cell Lung Cancer (NSCLC) | Do not reimburse | Complete | ||
Lorbrena | lorlatinib | ALK-positive locally advanced or metastatic non-small cell lung | Reimburse with clinical criteria and/or conditions | Complete | ||
Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete |